GLP-1: From Diabetes Niche to Obesity Blockbuster – The Next Pharma Supercycle

In the 20th century, humanity’s greatest healthcare challenge was communicable diseases, which were tackled with the discovery and widespread adoption of antibiotics. The introduction of penicillin alone improved life expectancy by nearly 30 years, lifting it from ~40 years in the early 1900s to ~70 years by 2000. With infectious diseases brought under control, the burden gradually shifted towards non-communicable diseases (NCDs) such as diabetes, obesity, cardiovascular ailments, and cancer—conditions that today account for most of the global morbidity and mortality. Just as antibiotics transformed outcomes for infectious diseases, the emergence of GLP-1 receptor agonists represents a similar inflection point in addressing the epidemic of NCDs, particularly obesity and diabetes, with the potential to significantly extend healthy life expectancy in the 21st century.

The Science Behind GLP-1 RA

GLP-1 is a naturally produced gut hormone. When a person eats, food travels down the digestive system to the GI tract and triggers the release of natural hormones called incretins. The two main incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These incretins then travel to the pancreas, liver, and stomach, causing several effects that help decrease blood glucose levels. Specifically, natural GLP-1 can:

• Delay gastric emptying, food stays in the stomach longer.

• Increase insulin production from pancreatic beta cells

• Decrease glucagon secretion from pancreatic α-cells, reducing glucose release by the liver.

• Signals satiety to the brain, leading to decrease in appetite.

GLP-1 Receptor Agonists are medications that are typically administered as subcutaneous injections (though an oral form also exists). Unlike natural incretins, which are released by the gut in response to food, GLP-1 receptor agonists are synthetic drugs that activate the GLP-1 receptor. By mimicking the effects of natural GLP-1, they enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

Initially approved for the management of Type 2 diabetes, GLP-1 agonists quickly gained prominence for their secondary benefit—weight loss.

Today, GLP-1 agonists are increasingly demonstrating “Molecular Swiss Army Knife”Effect with clinical data suggesting benefits not only in obesity but also in breaking the self-perpetuating cycle of obesity by helping solve for metabolic diseases (like cardiovascular, CKD, MASH). This positions the drug as a revolutionary to improve human healthcare.

GLP-1 Drug Landscape:

Currently, the GLP-1 drug market is dominated by two major innovators: Novo Nordisk and Eli Lilly. Novo Nordisk pioneered the space with the launch of Liraglutide (Victoza) in the early 2010s for Type-2 diabetes, followed by its weight-loss formulation Saxenda about 4–5 years later. However, GLP-1 drug class started gaining popularity nearly eight years later, with the introduction of Semaglutide (Ozempic) in February 2018. The key inflection point was a meaningful improvement in patient convenience—transitioning from a once-daily injection with Liraglutide to a once-weekly dosing regimen with Semaglutide.

Eli Lilly has accelerated the market’s growth trajectory with the launch of Tirzepatide, a next-generation dual incretin agonist. Clinical data highlights its superior efficacy, demonstrating 1.8–2.4% reductions in HbA1c and 18–21% weight loss, setting a new benchmark in both diabetes management and obesity treatment.

GLP-1s Have Taken the World by a Storm

Over the past decade, the GLP-1 therapeutics market has transformed from a $2 billion category in CY14 into a $74 billion annualized run-rate market by Q2CY25, reflecting one of the fastest growth trajectories. Notably, the market has doubled in size over just the last 18 months (from ~$36 billion in CY23), underscoring the acceleration phase currently underway.

The clear inflection point came with the launch of Semaglutide (Wegovy) for obesity in June 2021. While GLP-1s were originally positioned for Type-2 diabetes, the entry into the weight-loss segment fundamentally altered the growth profile. Sales effectively doubled YoY post-Wegovy launch, highlighting weight management as the dominant demand driver.

5 years since launch, weight-loss indications already account for ~35% of the total GLP-1 market—a remarkable shift that illustrates how obesity-focused therapies are reshaping category economics and expanding the addressable patient pool far beyond diabetes.

GLP-1s: A Demand Storm that Led to Massive Shortage

While the growth trajectory of GLP-1s has been extraordinary, demand was consistently underestimated. Innovators Novo Nordisk and Eli Lilly initially concentrated their commercial strategies on developed markets—primarily the U.S., with limited penetration in Canada and Europe—leaving RoW markets severely under-supplied.

Capacity bottlenecks quickly became apparent. The USFDA declared Wegovy in shortage by March 2022, followed by Ozempic in August 2022 and Tirzepatide in December 2022. Supply constraints proved persistent: Tirzepatide shortages extended for nearly two years, while Semaglutide (both Wegovy and Ozempic) only saw shortages resolved as recently as February 2025.

In the interim, compounding pharmacies stepped in to fill the gap. A compounding pharmacy is a pharmacy that makes custom versions of medicines when mass-produced drugs are unavailable or don’t meet a patient’s needs. Even though Novo Nordisk (Semaglutide) and Eli Lilly (Tirzepatide) hold patents and FDA approvals, compounding pharmacies were legally allowed to make versions if the branded drug is declared under shortage by USFDA. Once shortages resolve, compounded copies are generally not permitted unless medically justified. With widespread drug shortages, many U.S. compounding pharmacies began preparing versions of these drugs to meet patient needs. By 2024, players such as Hims & Hers were offering compounded Semaglutide formulations, which rapidly gained traction – Hims & Her’s Stock price went up from ~$13 in mid 2024 to ~$69 at its Feb’25 peak. As per Novo Nordisk, compounded Semaglutide represented ~1/3^rd of the US Semaglutide market at the peak of the shortage.

Recognizing that supply constraints had become the key bottleneck to growth, innovators have moved decisively to expand manufacturing capacity. In Feb 2024, Novo Nordisk announced the $16.5 billion acquisition of Catalent (deal closed in Dec’24), securing critical fill-finish and manufacturing capabilities. In parallel, Eli Lilly committed $30 billion in capital investments dedicated to scaling up GLP-1 production.

While innovators focus on defending share in developed markets, the Rest of World (RoW) is preparing for the genericization of Semaglutide, which is set to lose patent protection across 80+ emerging market countries as early as 2026.

Although Novo Nordisk’s Semaglutide patents remain secure in the USA, EU, and Japan through 2031–2032. However, in more than 80 countries including several emerging geographies, Semaglutide goes off-patent as early Jan 2026 due to procedural lapses, differing IP laws, or rejection of extension filings. Key markets were Sema goes off-patent include Canada (Jan’26), Brazil, China, India (March’26).

In contrast, Eli Lilly enjoys a more favorable patent runway. The base compound patent for Tirzepatide extends to 2036 and follow-on patents provide protection into the mid-2040s. This positions Lilly with a timing advantage, maintaining exclusivity well beyond Novo’s Semaglutide in many major markets.

Sizing the Opportunity:

Market Sizing for Diabetes: Globally, ~589 million adults live with diabetes. Only ~18% of this population resides in the U.S., Europe, and Canada, while ~82% are in Rest-of-World (RoW) markets. Due to supply shortages, both Novo Nordisk and Eli Lilly prioritized developed markets, given their higher commercial value, leaving RoW materially underserved. This is evident in adoption trends: GLP-1 penetration is ~19% in the U.S. and ~9% in Europe/Canada, compared with just ~0.6% in RoW.

Market Sizing for Obesity: The opportunity is even larger in obesity, with ~934 million adults worldwide living with the condition. Yet GLP-1 penetration remains nascent at just ~0.4% globally. The U.S., which accounts for ~12% of the world’s obese population, has GLP-1 penetration of only ~2%. Rest-of-World (RoW) markets represent ~78% of the addressable pool but have seen negligible uptake at just ~0.3%.

The significant under-penetration in RoW highlights a multi-decade growth runway and positions these markets as the next frontier for expansion. As Semaglutide begins to lose exclusivity across 80+ emerging markets from 2026, generic players have a strong Right to Win by capturing demand in these underserved geographies, while innovators remain focused on maximizing value in developed markets.

Opportunity for India’s Domestic Pharma Market

India, often referred to as the “diabetes capital of the world,” represents one of the most attractive markets for GLP-1 therapies. Historically dominated by generics, Indian pharma players are expected to aggressively pursue this category, while innovators have only recently begun to establish a direct presence. Novo Nordisk and Eli Lilly have launched Wegovy (Jun’25) and Mounjaro (Mar’25), respectively, marking a strategic push into this high-potential market.

The GLP-1 drugs market in India stood at ~₹450Cr in FY25, driven primarily by Rybelsus (oral Semaglutide) and Liraglutide. With the recent entry of Mounjaro and Wegovy, annualized sales as of August 2025 has more than quadrupled to ~₹2,040Cr.

Mounjaro has been a breakout success: Launched in March 2025, it reached ~₹118Cr in monthly sales by August 2025, generating cumulative sales of ~₹303Cr within just 6 months and becoming India’s No. 1 pharma brands. Notably, this momentum was achieved despite being available only in the vial dosage format; the more convenient pen format has just been introduced. For context, Augmentin, India’s largest pharma brand as captured by secondary databases, currently has annual sales of ~₹900Cr, despite being launched over three decades ago. India’s largest innovator brand Keytruda (oncology drug) has sales of ~$200mn. Given Mounjaro’s trajectory of sales so far, and the rollout of pens, it could potentially become India’s biggest ever pharma blockbuster drug.

Meanwhile, Wegovy, launched in June 2025, has already achieved cumulative sales of ~₹21Cr in its first three months, underscoring rising demand for obesity treatments.

Quantifying GLP-1 India Market Opportunity

While diabetes has been the traditional entry point for GLP-1s, obesity represents an even larger incremental upside given its higher target pool. Combined, India’s potential GLP-1 patient base could be 70lakh to 1.2crore across diabetes and obesity, representing a multi-billion market opportunity.

GLP-1s are expected to evolve into a high-volume market in India, with generic entrants likely to price their products at a steep discount: 70–80% below innovator pricing. The experience with SGLT2 inhibitors provides a clear precedent: following the 2020 patent expiry of Dapagliflozin, the market witnessed an 8x increase in sales and a 26x surge in volumes over five years, with generics launched at ~70% discount to the innovator. This demonstrates how price correction post-patent expiry can unlock exponential volume growth in chronic therapies.

As Semaglutide loses exclusivity in 2026, affordability will improve significantly, enabling much broader adoption. With potential for massive volumes to serve India’s diabetic & Obese patient pool, GLP-1 market in India has the potential to double the anti-diabetic market over the next five years.

The GLP-1 value chain presents a multi-layered opportunity for Indian players, spanning APIs, devices, fill-finish, and commercial marketing. Collectively, this ecosystem positions India not just as a cost-efficient manufacturing hub but also as a strategic participant in the global GLP-1 supply chain, with opportunities across both export and domestic markets.

• APIs: Companies such as Divi’s, Piramal, Neuland, Dr. Reddy’s, Biocon, and Eris (via its stake in Levim) are investing in capacity to capture both innovator and future generic API demand.

• Devices: Shaily Engineering has emerged as a key supplier, leveraging its deep expertise in pen and injector manufacturing.

• Fill-finish: A critical bottleneck globally – Players like Gland Pharma, Eris, and Onesource have invested in capacity

• Commercial/marketing: Most leading Indian pharma companies have expressed intent to launch generics in key markets as patents expire.

  
  

In conclusion, the emergence of GLP-1 receptor agonists marks a pivotal inflection point – potentially the beginning of a new pharma supercycle. Initially developed as therapies for Type-2 diabetes, GLP-1s have rapidly evolved into a transformative solution for obesity and demonstrates strong potential across other indications, including cardiovascular disease and chronic kidney disease. Today, the market is dominated by two innovators—Novo Nordisk and Eli Lilly—with seven approved brands. Yet this is only the start: more than 30 GLP-1 assets are in clinical development, targeting a broad spectrum of conditions.

From 2026 onwards, the landscape will shift meaningfully as Semaglutide begins to lose exclusivity in emerging markets. The entry of generics is expected to materially lower prices, improve affordability and expand access. In India, this could catalyse a significant demand surge, with the GLP-1 therapies set to accelerate IPM growth & potentially double the anti-diabetic market.

For investors, the opportunity is multi-faceted. Beyond innovators and generics, value creation extends across the full GLP-1 value chain—APIs, devices, fill-finish, and CDMOs—positioning the segment as one of the most compelling growth stories in global healthcare over the coming decade.